je.st
news
Tag: study
US Ecology, Inc. (ECOL) - Clean Technology - Deals and Alliances Profile - New Market Study Published
2015-06-01 05:30:13| Waste Management - Topix.net
The company provides waste disposal and recycling services. Its services portfolio includes hazardous waste treatment & disposal, low-activity radioactive waste disposal, low-level radioactive waste disposal, hydrocarbon recycling services, PCB waste services, transportation, on-site services, total waste solutions program, lab support, beneficial re-use and waste water treatment.
Tags: new
profile
technology
market
TETRA Technologies, Inc. (TTI) - Oil & Gas - Deals and Alliances Profile - New Market Study Published
2015-06-01 04:44:49| Chemicals - Topix.net
It offers a wide range of services including production well testing, compression-based production enhancement, decommissioning, water management, cooling, after-frac flow back, and selected offshore services, among others. The company's operations are composed of five reporting segments organized into three divisions, namely, Fluids, Production Enhancement, and Offshore.
Tags: new
profile
market
study
TESARO and Merck to Collaborate on a Combination Study of Niraparib and KEYTRUDA (pembrolizumab)
2015-05-30 20:00:20| Merck.com - Product News
Dateline City: WALTHAM, Mass., and KENILWORTH, N.J. Clinical Trial Will Evaluate TESAROs PARP Inhibitor with Mercks Anti-PD-1 Therapy in Patients with Breast and Ovarian Cancers WALTHAM, Mass., and KENILWORTH, N.J., May 30, 2015 TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced a collaboration to evaluate the combination of TESAROs niraparib plus Mercks anti-PD1 therapy, KEYTRUDA (pembrolizumab), in a Phase 1/2 clinical trial. Language: English read more
Tags: study
combination
collaborate
merck
First Study Evaluating DNA Mismatch Repair as Genetic Guide for Immunotherapy Treatment with Mercks KEYTRUDA (pembrolizumab) Presented at 2015 ASCO Annual Meeting and Published in the New England Journal of Medicine
2015-05-29 20:05:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Early Findings Show DNA Mismatch Repair-Deficient Colorectal and Other Tumors Highly Responsive to Checkpoint Blockade with Anti-PD-1 Therapy Merck Plans to Initiate Phase 2 Registrational Study with KEYTRUDA (KEYNOTE-164) to Evaluate MMR-Deficiency in Colorectal Cancer KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the first study evaluating the correlation of benefit with an immunotherapy based on DNA mismatch repair (MMR) deficiency, a well-established form of genetic instability in many cancers characterized by the loss of function of the MMR pathway. Language: English Contact: MerckMedia:Pamela Eisele, 267-664-0282Claire Mulhearn, 908-200-1889orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
UK study provides observational evidence linking ocean circulation to weather and decadal-scale climate change
2015-05-28 16:55:33| Green Car Congress
Tags: change
study
evidence
weather
Sites : [465] [466] [467] [468] [469] [470] [471] [472] [473] [474] [475] [476] [477] [478] [479] [480] [481] [482] [483] [484] next »